Mechanism of Action of Jardiance (Empagliflozin)

Introduction

Jardiance (empagliflozin) is a sodium–glucose co-transporter 2 (SGLT2) inhibitor used for type 2 diabetes mellitus (T2DM), heart failure with reduced ejection fraction (HFrEF), and chronic kidney disease (CKD). It lowers blood glucose by increasing renal glucose loss and offers cardiovascular and renal benefits.

---

Step-by-Step Mechanism of Action

1. Selective inhibition of SGLT2 in proximal tubules
   Empagliflozin blocks the SGLT2 transporter in the early proximal convoluted tubule of the kidney, preventing reabsorption of filtered glucose and sodium.
2. Increased urinary glucose excretion
   Blocking SGLT2 results in excretion of about 60–80 g of glucose daily, lowering plasma glucose and reducing HbA₁c.
3. Osmotic diuresis and natriuresis
   Glucosuria induces an osmotic diuretic effect, promoting sodium loss, reducing blood volume and preload, and lowering blood pressure.
4. Weight reduction and metabolic improvements
   Loss of calories via glucosuria contributes to weight loss and improves glycemic control and insulin sensitivity.
5. Cardiorenal protective effects
   Empagliflozin reduces intraglomerular hypertension, decreases albuminuria, and lowers heart failure hospitalizations—likely via hemodynamic and metabolic mechanisms.

---

Pharmacokinetic Parameters

Parameter	Value
Route	Oral (tablet), once daily
Bioavailability	~78%
Time to Peak (Tmax)	~1.5 hours
Protein Binding	~86%
Metabolism	Minimal via glucuronidation (UGT2B7, UGT1A3/1A8/2B4)
Half-life	~12 hours
Excretion	~54% urine (unchanged), ~41% feces

---

Clinical Uses

• Glycemic control in type 2 diabetes
• Reduction in HFrEF-related cardiovascular death and hospitalization, with or without diabetes
• Delay progression of chronic kidney disease

---

Adverse Effects

• Genitourinary infections: yeast infections and UTIs
• Volume depletion: hypotension, dizziness
• Rare cases of euglycemic diabetic ketoacidosis
• Slight increases in LDL cholesterol and magnesium

---

Comparative Analysis

Agent	Selectivity	HbA₁c Reduction	Weight Loss	Cardiorenal Benefit
Empagliflozin (Jardiance)	High SGLT2 selectivity	0.5–1.0%	2–3 kg	Yes
Canagliflozin	SGLT2 ≈ SGLT1	0.8–1.1%	2.5–3.5 kg	Yes
Dapagliflozin	SGLT2 > SGLT1	0.5–1.0%	2–3 kg	Yes

---

MCQs

1. Empagliflozin inhibits which transporter?
   a) SGLT1 b) SGLT2 c) GLUT2 d) Na⁺/K⁺ ATPase
   Answer: b) SGLT2
2. Daily urinary glucose loss is approximately:
   a) 20 g b) 40 g c) 60–80 g d) 100 g
   Answer: c) 60–80 g
3. The diuretic effect arises from:
   a) Loop diuretic action b) Osmotic diuresis c) Thiazide-like effect d) Aldosterone antagonism
   Answer: b) Osmotic diuresis
4. Weight loss with empagliflozin is due to:
   a) Appetite suppression b) Caloric loss via glucosuria c) Metabolic rate increase d) Lipid absorption blockade
   Answer: b) Caloric loss via glucosuria
5. Cardiorenal benefits include:
   a) Increased albuminuria b) Reduced hospitalizations c) Higher blood pressure d) Reduced LDL only
   Answer: b) Reduced hospitalizations
6. Metabolism primarily occurs via:
   a) CYP3A4 b) Glucuronidation c) CYP2D6 d) Renal excretion unchanged
   Answer: b) Glucuronidation
7. Excretion route includes:
   a) Mainly renal b) Mainly biliary c) Equally renal & fecal d) Pulmonary
   Answer: c) Equally renal & fecal
8. A rare but serious side effect is:
   a) Hyperglycemia b) Euglycemic ketoacidosis c) Hypothyroidism d) Liver injury
   Answer: b) Euglycemic ketoacidosis
9. Protein binding is about:
   a) 50% b) 70% c) 86% d) 99%
   Answer: c) 86%
10. Time to peak plasma concentration is:
    a) 30 min b) 1.5 hrs c) 5 hrs d) 12 hrs
    Answer: b) 1.5 hrs

---

FAQs

1. Can empagliflozin be used without diabetes for heart failure?
Yes—it’s approved for HFrEF regardless of diabetic status.

2. Should renal function be monitored?
Yes—check baseline and periodically, especially in CKD patients.

3. Is empagliflozin associated with hypoglycemia?
Not when used alone; risk increases with insulin or sulfonylureas.

4. How soon are cardiorenal benefits seen?
Clinical benefits often begin within a few months.

5. How long should treatment continue?
Long-term use is common; discontinuation may be considered if no benefit or side effects occur.

---

References

• Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 13ᵗʰ Edition
• KD Tripathi. Essentials of Medical Pharmacology, 8ᵗʰ Edition
• DrugBank: Empagliflozin pharmacology summary
• StatPearls: Empagliflozin mechanisms and clinical effects
• PubMed review: Cardiorenal safety of empagliflozin